VTGN News and Press, VistaGen Therapeutics Inc. From 06/16/21

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxi...

VistaGen Therapeutics (VTGN) announces the initiation of its PALISADE Phase 3 clinical program with a late-stage, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PH94B for the acute treatment of adults with Social Anxiety Disorder ((SAD)).PH...

PALISADE Phase 3 Program focused on acute treatment of anxiety in adults with Social Anxiety Disorder FDA Fast Track designation granted Topline results anticipated in mid-2022 SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc....

Penny Stocks To Buy According To Top Wall Street Firms What do you look for when it comes to finding penny stocks to buy? Are you hunting for momentum? Should corporate filings be part of your research? Will news headlines play a role in your decision-making? What about industry sentime...

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will present at two invest...

Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervou...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back once again, investors, and let’s get ready for a busy day of trading! We’re kicking off the day with a look at the biggest pre-market stock movers for Thursday below. Source: oneinchpunch/Shut...

Baird has initiated shares of VistaGen Therapeutics (VTGN) with an outperform rating, calling the stock "significantly undervalued" and "a big outperformer over the next year."Analyst Brian Skorney has a $9 price target, implying a 291% return from today's close.Skorney highlights the potenti...

Shares of VistaGen Therapeutics (VTGN) are down 1.4% in after-hours trading after announcing it had filed for a $75M at-the-market offering.Jefferies will act as sales agent.VistaGen shares closed down 18.7% for the week but are up 9.8% year-to-date. For furthe...